IBD: the perfect example of translational medicine?
The genetic and clinical heterogeneity of IBD means translational research has a key role to play. A session dedicated to translational and basic science at UEG Week 2019… read more.
The genetic and clinical heterogeneity of IBD means translational research has a key role to play. A session dedicated to translational and basic science at UEG Week 2019… read more.
An oral abstract session dedicated to patient-reported outcomes (PROs) in IBD included surveys from France and the Netherlands and from the multi-centre ICONIC study.. Written by Maria Dalby
Dr Maria Abreu (Miami, USA) gives us an overview of implementing disease monitoring and its challenges in clinical practice Written by Maria Dalby
A subcutaneous formulation of infliximab, known as CT-P13 SC, has been developed with a view to offer greater flexibility and convenience for patients.
In a round-up of randomised controlled studies in IBD at UEG Week 2019 included results from the maintenance phase of the UNIFI study in UC and a phase-3… read more.
Professor Jean-Frédéric Colombel (Icahn School of Medicine at Mount Sinai, New York, USA) opened the symposium with an overview of how treatment targets in UC have evolved from improving… read more.
UEGW 2019, held in Barcelona, Spain, was a very interesting meeting, covering a wide range of hot topics from the world on IBD. The meeting was well-attended with… read more.
Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.
Tumours use a variety of mechanisms to escape the host immune system and overcoming these to increase response rates and improve quality of life are key goals. Manipulation… read more.
Targeted treatments for mutation-driven non-small cell lung cancer have advanced considerably but many questions remain about how to use these drugs to the best advantage and how to… read more.
Immunotherapy has been hailed as a “game changer” in the treatment of lung cancer. As experience and understanding grows, optimal ways of delivering this type of treatment are… read more.
Immunotherapy now has an established place in treatment of non-small cell lung cancer but many questions remain such as the role of tumour mutational burden as a biomarker… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.